Synairgen announces data from Home Cohort of SG016 Phase II trial of inhaled interferon beta in COVID-19 patients and encouraging combined data for whole SG016 trial
30 avr. 2021 02h00 HE
|
Synairgen plc
Press release Synairgen plc(‘Synairgen’ or the ‘Company’) Synairgen announces data from Home Cohort of SG016 Phase II trial of inhaled interferon beta in COVID-19 patients and encouraging...
Synairgen announces that dosing has commenced with its inhaled interferon beta product in US Government-funded NIH ACTIV-2 trial in COVID-19 outpatients
15 févr. 2021 07h00 HE
|
Synairgen plc
Press release Synairgen plc(‘Synairgen’ or the ‘Company’) Synairgen announces that dosing has commenced with its inhaled interferon beta product in US...
Synairgen announces that dosing has commenced with its inhaled interferon beta product in US Government-funded NIH ACTIV-2 trial in COVID-19 outpatients
15 févr. 2021 02h00 HE
|
Synairgen plc
Press release Synairgen plc(‘Synairgen’ or the ‘Company’) Synairgen announces that dosing has commenced with its inhaled interferon beta product in US...
Synairgen announces inclusion of its inhaled interferon beta treatment in US NIH ACTIV-2 trial in COVID-19 outpatients
25 janv. 2021 07h00 HE
|
Synairgen plc
Press release Synairgen plc(‘Synairgen’ or the ‘Company’) Synairgen announces inclusion of its inhaled interferon beta treatment in US NIH ACTIV-2 trial in COVID-19 outpatients ACTIV partnership is...
Synairgen announces inclusion of its inhaled interferon beta treatment in US NIH ACTIV-2 trial in COVID-19 outpatients
25 janv. 2021 02h00 HE
|
Synairgen plc
Press release Synairgen plc(‘Synairgen’ or the ‘Company’) Synairgen announces inclusion of its inhaled interferon beta treatment in US NIH ACTIV-2 trial in COVID-19 outpatients ACTIV partnership is...
Synairgen announces completion of recruitment into its Phase II Home-Based COVID-19 study of inhaled interferon beta
20 janv. 2021 07h00 HE
|
Synairgen plc
Press release Synairgen plc(‘Synairgen’ or the ‘Company’) Synairgen announces completion of recruitment into its Phase II Home-Based COVID-19 study of inhaled interferon beta - Establishing proof...
Synairgen announces completion of recruitment into its Phase II Home-Based COVID-19 study of inhaled interferon beta
20 janv. 2021 02h00 HE
|
Synairgen plc
Press release Synairgen plc(‘Synairgen’ or the ‘Company’) Synairgen announces completion of recruitment into its Phase II Home-Based COVID-19 study of inhaled interferon beta - Establishing proof...
Synairgen announces commencement of dosing in its international Phase III study of inhaled interferon beta in hospitalised COVID-19 patients
13 janv. 2021 07h00 HE
|
Synairgen plc
Press release Synairgen plc(‘Synairgen’ or the ‘Company’) Synairgen announces commencement of dosing in its international Phase III study of inhaled interferon beta in hospitalised COVID-19 patients...
Synairgen announces commencement of dosing in its international Phase III study of inhaled interferon beta in hospitalised COVID-19 patients
13 janv. 2021 02h00 HE
|
Synairgen plc
Press release Synairgen plc(‘Synairgen’ or the ‘Company’) Synairgen announces commencement of dosing in its international Phase III study of inhaled interferon beta in hospitalised COVID-19 patients...
COVID-19 Clinical Programme Update
18 déc. 2020 07h00 HE
|
Synairgen plc
Press release Synairgen plc(‘Synairgen’ or the ‘Company’) COVID-19 Clinical Programme Update SNG001 given Fast Track designation and IND cleared by the US FDAPhase III trial design adapted which...